CD47 and neoplasm: The recently emerging immune checkpoint CD47 has been shown to be vital in circumventing immune surveillance of various tumors, and CD47 blockade enhances phagocytosis of myeloid cells to tumor cells, promoting the antigen cross presentation of antigen presenting cells, thus initiating T cell function and activating adaptive immune response.